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tackling solubility and permeability hurdAbstract Oral drug absorption is a process inﬂuenced by the physicochemical and biopharmaceutical
properties of the drug and its inter-relationship with the gastrointestinal tract. Drug solubility, dissolution
and permeability across intestinal barrier are the key parameters controlling absorption. This review
provides an overview of the factors that affect drug absorption and the classiﬁcation of a drug on the basis
of solubility and permeability. The biopharmaceutical classiﬁcation system (BCS) was introduced in early
90's and is a regulatory tool used to predict bioavailability problems associated with a new entity, thereby
helping in the development of a drug product. Strategies to combat solubility and permeability issues are
also discussed.
& 2016 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical
Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Table 1 Evolution of BCS.
Year Prominent research Ref.
1897 Noyes-Whitneys ﬁrst experiment on dissolution 3
1904 Nernst-Brunner diffusion layer concept 4
1931 Hixon-Crowell model 5
1950 Ofﬁcial disintegration test in USP 6
1951 Danckwert's theory 7
1961 Higuchi's interfacial barrier model 8
1970 Dissolution apparatus I (Basket type) 9
1978 Dissolution Apparatus II (Paddle type) 9
1981 FIP guidelines for dissolution of solid dosage
form
10
1985 General chapter on “drug release” in USP 9
1991 USP dissolution apparatus III “reciprocating
cylinder type”
9
1995 USP dissolution apparatus IV “ﬂow through
cell”
9
1995 Amidon Gordan introduced BCS 11
2000 FDA introduced BCS guidelines 121. Introduction
Peroral administration is the predominantly acceptable route of
drug administration owing to its beneﬁts such as self administra-
tion with minimal discomfort to patients, which improves patient
compliance, makes it cost effective and provides ﬂexibility in
design of dosage form1. There are various factors which control of
absorption through the oral route and thus affect the bioavailability
of a drug. FDA deﬁnes bioavailability as “the rate and extent to
which the active ingredient or active moiety is absorbed from a
drug product and becomes available at the site of action”. A prior
knowledge of biopharmaceutical optimization and in vivo avail-
ability of drug were ﬁrst only on focused disintegration time while
ignoring fundamental factors like dissolution. Researchers tried to
mimic the biological conditions like gut pH, food content and
peristalsis for precisely predicting in vivo performance. In the
years 1960–1970, several studies were carried out which demon-
strated the effect of dissolution, formulation parameters [excipi-
ents, slight change in concentration of active pharmaceutical
ingredient (API), dosage form, etc.] and food on bioavailability.
Bioavailability concerns and quality control consideration further
initiated the need for an ofﬁcial dissolution test. The ﬁrst
dissolution test apparatus, basket stirred ﬂask type (USP apparatus
I) was introduced in 1970 and subsequently paddle type (USP
Apparatus II) in 19782. In vitro tests have been successful in
predicting in vivo performance of dosage forms. Despite the
complexity of the factors, progress has been made to improve
the performance of dosage forms in vivo. Some of the prominent
research carried out in this ﬁeld is listed chronologically in
Table 13-12.
This article reviews the drug absorption process which depends
upon drug properties, such as solubility and permeability, physio-
logical factors like pH, regional permeability differences, food
effects and formulation factors. Combinatorial chemistry and high
throughput screening has led to the development of lead drug
compounds having higher molecular weight, poor wetting proper-
ties and high lipophilicity, thus placing 40% of lead candidates
into Biopharmaceutical Classiﬁcation System (BCS) class II and
class IV. Better understanding of the various factors during the
lead optimization phase can help to reduce the cost of develop-
ment. The other approach to address poor solubility and perme-
ability issues is to modify the drug by using different formulation
approaches. This review provides insight on fundamentals of BCS
and a literature database of formulation strategies used to managechi, Pokharkar Varsha. Understanding
les. Acta Pharmaceutica Sinica B (solubility and permeability problems. These approaches can help
in shifting the lead candidate to a better class of BCS.2. Movement of drug through the gastrointestinal tract
Fig. 1 shows the journey of a drug through the gastrointestinal (GI)
tract. The GI tract is a complex system; the ﬁrst organ which a
drug encounters is the stomach, which contains many digestive
enzymes, has an acidic environment (pH 1.5–3.5) and very few
drugs are absorbed through stomach. The small intestine (duode-
num, jejunum, and ileum) is the major site for drug absorption.
Dosage form disintegration and dissolution, degradation, binding
in the intestinal lumen, intestinal permeation and intestinal and
hepatic metabolism controls the pharmacological activity and
transition of a drug in the GI tract13,14. Also, these processes in
the GI tract are interlinked and controlled by various factors like
physicochemical, physiological and the type of dosage form
(tablet, capsule, solution, suspension, emulsion, and gel)15,16.
Physicochemical factors include pKa, solubility, stability, diffusiv-
ity, lipophilicity, polar and nonpolar surface area, the presence of
hydrogen bonding functionalities, particle size, and crystal form,peroral absorption: Regulatory aspects and contemporary approaches to
2016), http://dx.doi.org/10.1016/j.apsb.2016.09.005
Figure 1 Journey of drug in gastrointestinal tract.
Understanding peroral absorption: regulatory aspects and contemporary approaches 3whereas physiological factors includes GI pH, GI blood ﬂow,
gastric emptying, small intestinal transit time, colonic transit time,
and absorption mechanisms.
Achieving sufﬁcient absorption and a reproducible pharmaco-
kinetic proﬁle in humans has become a hurdle in developing oral
drug delivery systems due to introduction of high throughput
screening and combinatorial chemistry, which has increased the
number of lipophilic and higher mass molecules17. A drug exerts
its pharmacological effect only when it binds to speciﬁc receptor,
for which it has to be in solubilized form and then should be able
to traverse the intestinal barrier. This implies that only a drug
which is in soluble form will be available for the absorption
process. Thus solubility and dissolution are the major rate-limiting
steps and are key parameters in preformulation studies at the early
development phase18,19. Dissolution is the process by which the
drug is released, dissolved and becomes readily available for
absorption. The rate of dissolution is greatly affected by the
solubility of the API, as explained by Noyes and Whitney's
postulate (1897)20 which states that “the rate at which solid
substance dissolves in its own solution is proportional to difference
in the concentration of that solution and concentration of saturated
solution. Nernst and Brunner (1904)4,21 later modiﬁed Noyes and
Whitney's equation by incorporating the value of surface area
accessible to dissolution.
dC=dt¼DS CsCbð Þ=Vh ð1Þ
where C is amount of drug dissolved (usually in mg or mmol) in time
t (s), D is the diffusion coefﬁcient of the drug (cm2/s), S is surface area
(cm2), h is thickness of the liquid ﬁlm, Cs and Cb are the
concentrations of the drug at the surface of the particle and the bulk
medium, and V is the volume of dissolution medium. The other
important factor is ”drug permeability” which is referred as ability of
drug molecule to permeate through a mucosal barrier into the systemic
circulation. The major site for absorption being epithelial cell in gut
wall within the small intestine provides a high surface area because of
microvilli present. The microvilli have glycoproteins protruding in the
luminal ﬂuid and consist of goblet cells which releases mucus, a gel
like structure containing water (95%) and mucin which blankets thePlease cite this article as: Shekhawat Prachi, Pokharkar Varsha. Understanding
tackling solubility and permeability hurdles. Acta Pharmaceutica Sinica B (surface. This glycoprotein and mucous forms an unstirred water layer
(UWL) with a thickness of 100 μm22. UWL in GIT is a signiﬁcant
barrier to drug absorption for lipophilic drugs23. Drug transport occurs
through the apical side of the enterocyte membrane and then across a
mucosal barrier (polarized enterocytes) crossing the basolateral
membrane and entering the systemic circulation via the capillary
network surrounding the enterocytes and hepatic portal vein. These
enterocytes are closely linked, producing the tight junctions. Tight
junctions are, in reality, small aqueous-ﬁlled pores with dimensions in
the range of 3–10 Âe which depends upon the membrane type. Drug
molecule can cross a biological membrane by transcellular or
paracellular mechanisms (passive diffusion). Transcellular absorption
occur through enterocytes, which may be by passive diffusion, carrier-
mediated transport and endocytosis. Passive diffusion of a drug is
driven by concentration gradient wherein drug moves from higher to
lower concentration, thus following Fick's law of diffusion. Carrier-
mediated transport involves the interaction of the carrier protein with
drug, which may be either a facilitated or an active process. Facilitated
carrier-mediated transport occurs through passage of a drug down its
electrochemical gradient without utilization of energy. In contrast,
active carrier-mediated transport involves an energy-coupling mechan-
ism that creates an ion/solute gradient across the membrane. The third
transcellular absorption mechanism is endocytosis which involves
internalization of a drug inside the cell by a forming membrane-bound
vesicle known as an endosome. Endocytosis can be divided into two
broad categories, i.e., phagocytosis (uptake of large particles) and
pinocytosis (uptake of solute and single molecules). The reticuloen-
dothelial system is only capable of phagocytosis, such as by
macrophages, neutrophils, monocytes and dendritic cells, while
pinocytosis is further classiﬁed into clathrin-mediated endocytosis
and clathrin-independent endocytosis. Another classiﬁcation of endo-
cytosis is based on interaction with cellular membrane which involves
receptor-mediated endocytosis (drug reacts with a speciﬁc surface
receptor) and absorption-mediated endocytosis (non-speciﬁc interac-
tion with a surface receptor)24. Many compounds can be absorbed by
the paracellular route but the process is invariably slower than the
transcellular route (surface area of pores versus surface area of the
membrane) and is dependent on molecular size due to the ﬁniteperoral absorption: Regulatory aspects and contemporary approaches to
2016), http://dx.doi.org/10.1016/j.apsb.2016.09.005
Table 2 Efﬂux and inﬂux drug transporters29,31,33.
Transporter Subtype (No. of
isoform)
Gene Symbol Localization Substrate drug
Peptide transporter PEP1 SLC15A Apical side of intestine β-Lactum antibiotic, angiotensin converting enzyme inhibitor, cephalosporins, rennin inhibitor,
oseltamivir, thrombin inhibitor, betastin, L-α-methyldopa-phenylalanine, D-phenylglycine-L-α-
methyldopa, L-valacyclovir
PEPT2
PTR3
hPT-1
PHT1
Nucleoside transporter CNT1 SLC28A Apical side of intestine Azidothymidine (AZT), zalcitabine, cladribine, cytarabine, gemcitabine, 5ʹ-deoxy-5-
ﬂurouridine
CNT2 – Cladribine, didanosine
CNT3 – 5-Flurouridine, ﬂoxuridine, zebularine, gemcitabine, AZT, cladribine
ENT1 SLC29A Cladribine, cytarabine, ﬂudarabine, gemcitabine, zalcitabine, didanosine
ENT2 – AZT, didanosine, gemcitabine
ENT3 –
Organic cation transporters OCT1/2 SLC22A Basolateral side of intestine Tetraethylammonium (TEA), thiamine, tyramine, tryptamine, N-methylnicotineamide (NMN),
choline, spermine, spermidine quinine, D-tubocurarine, procainamide, dopamine, noradrenaline,
serotonine, histamine, corticosterone, 1-methyl-4-phenylpyridinium (MPP), desipramine,
metformin, acyclovir, ranitidine, memantine
OCT 3 – – Dopamine, MPP, TEA, guanidine
OCTN1 SLC22A – TEA, pyrilamine, quinidine, ergothioneine, verapamil
OCTN2 – – Carnitine derivative, betaine, cephaloridine, choline, emetine, pyrilamine, quinidine, TEA,
valproate, verapamil, imatinib, ipratropium
OCTN3 – – Carnitine
Organic anion transporter OAT1 SLC22A Apical side of intestine p-Aminohippurate (PAH), methotrexate, β-lactum antibiotics, non-steroidal anti-inﬂammatory
drugs, antiviral nucleoside analogues
OAT2 – Methotrexate, PAH, salicylate
OAT3 – Estrone sulfate, ochratoxin A, cimetidine
OATP1/2 SLC21A Bromosulfophthalein (BSP), pravastatin, temocaprilat, estradiol 17β-glucuronide (E217G),
enalapril, gadoxetate, dehydroepiandrosterone sulfate
hOATPs – BSP, taurocholate, glycocholate, estrone sulfate, dehydroepiandrosterone sulfate, ouabain, N-
methyl quinidine, prostaglandine E2, triiodothyronine, thyroxine, deltorphin II, D-penicillamine,
enkephalin, fexofenadine, rifampin, rocuronium, quinidine, methotrexate, pravastatin, digoxin
Glucose transporter SGLTs (3) SLC5A Apical side of intestine Inositol, proline, pantothenatem iodide, urea, glucose derivative
GLUTs (13) SLC2A Basolateral side of
intestine
Vitamin transporter SVCTs (2) SLC23A – Ascorbic acid derivative
RFC1 SLC19A Reduced folate derivatives, methotrexate
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SMVT SLC5A6 Pantothenate, biotin, lipoate
Bile acid transporter NTCP SLC10A Basolateral membrane of
hepatocyte
Steroids and steroid conjugates, cyclic peptides, bumetanide, BSP
ISBT SLC10A Ileum brush border membrane Peptide drugs
Fatty acid transporter FATPs (6) SLC27A Apical side of enterocytes Long chain fatty acids, like myristate and palmitate
Phosphate transporter SLC17As (4) SLC17A Brush border membrane Foscarnet, fosfomycin
SLC34As (2) SLC34A
Monocarboxylic acid
transporter
MCTs (6) SLC16A Apical side of enterocytes Atorvastatin, valproic acid, pyruvic acid, benzoic acid
ABC transporter MDR1/P-gp ABCB1 Apical side of enterocytes Steroid hormone, bile salts, glycocholate, doxorubicin, ciproﬂoxacin, etoposide
tauroursodeoxycholate, daunorubicin, reserpine, vincristine, Vinblastine, valinomycin,
cyclosporine, tacrolimus, tandutinib, aldosterone, hydrocortisone, dibucaine, talinolol, digoxin,
ivermectin, paclitaxel, grepaﬂoxacin, indinavir, nelﬁnavir, saquinavir, colchicines, darunavir,
ﬂavonoids, glyburide, methotrexate, mitoxantrone, prazosin, temocapril, celiprolol
BCRP ABCG2 Apical side of enterocytes Topotecan, irinotecan, doxorubicin, daunorubicin, doxorubicin, imatinib, geftinib, tandutinib,
statins, prazosin, glyburide, dipyridamole, quercetin, temocapril, sulfate conjugates, porphyrin,
nitrofurantoin, ﬂuroquinolones, zidovudine, lamivudine, efavirenz, ciproﬂoxacin, rifampicin,
sulfasalazine, quercetin, resveratrol conjugates.
MRP2 ABCC1 Apical side of enterocytes Leukotrienes glutathione, 2,4-dinitrophenyl-S-glutathione, bromosulfophthalein, conjugates of
bile salts and heavymetals, resveratrol conjugates, naringenin glucoronides, vinblastine, reduced
folates, pravastatin, ceftriaxone, ampicillin, grepaﬂoxacin, sulfasalazine, fexofenadine,
lopinavir, fosinopril, ochratoxin A, epicatechin, phenols, colchicines, darunavir, ﬂavonoids,
methotrexate
– Not available.
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Prachi Shekhawat, Varsha Pokharkar6dimensions of the aqueous pores. Whether a drug diffuses via a
passive transcellular mechanism or a paracellular mechanism is
determined by both physiological and physicochemical factors25,26.
During transition of a drug through the enterocyte membrane, it may
undergo gut membrane metabolism by cytochrome P450 (CYP)
enzymes and may encounter both efﬂux and absorptive transporters27.
Speciﬁc transporters are expressed in different regions including
luminal and basolateral membranes of enterocytes, hepatocytes, renal
tubular epithelial cells and other important barrier tissues including the
blood–brain barrier, blood–testis barrier and placental barrier28.
According to the guidelines of the Human Genome Organization
(HUGO) Gene Nomenclature Committee, 229 solute carrier (SLC)
family genes and 52 ATP-binding cassette (ABC) genes have been
identiﬁed29. The major uptake transporters responsible for xenobiotic
transport belongs to the two solute carrier (SLC and SLCO)
subfamilies. These subfamilies are involved in transport of wide
variety of substrates like amino acids, peptides, sugars, vitamins, bile
acids, neurotransmitter and xenobiotics. Solute carriers, known to play
a relevant role in drug transport in the intestine, include the
oligopeptide transporter (PEPT), organic cation/carnitine transporter
(OCTN), organic cation transporter (OCT), plasma membrane mono-
amine transporter (PMAT), organic anion transporting protein (OATP)
and the monocarboxylate transporter (MCT)30. The most investigated
and highly abundant transporters at the luminal membrane of
enterocytes (intestine) are the efﬂux transporter P-glycoprotein (P-
gp), the multidrug resistance associated protein 2 (MRP 2) and the
breast cancer resistance protein (BCRP) of the ABC family. Many
drugs such as statins, antibiotics, HIV protease inhibitors, immuno-
suppressant and anticancer drugs are substrates for efﬂux transporters
(P-gp, MRP 2, BCRP) which place them back into the gut lumen from
where they can be excreted31,32. Table 2 shows various membrane
transporters, their subfamilies and substrate drugs29,31,33. Drug leaving
the enterocyte then enters the hepatic portal vein by which it is
transported to the liver. Liver either metabolizes it or excrete it
unchanged into the bile which is termed hepatic ﬁrst pass metabolism.
Thus, oral bioavailability of a drug is determined by the amount
absorbed from GIT (Fa), the fraction escaping ﬁrst pass extraction by
the gut (Fg), and the fraction escaping ﬁrst pass extraction by the liver
(Fh) as given by following Eq. (2):
Fraction bioavailability¼ Fa  Fb  Fh ð2ÞTable 3 Fed and fasted state variables47.
Position Fasted state Fed state
Stomach
Fluid volume 50–100 Upto 1000
pH 1–2 2–5
Ionic strength 0.1 Varying
Motility pattern/
intensity
Cyclic/low–
high
Continuous/high
Surface tension (mN/
m)
40 Often lower than
fasted
Osmolarity (mOsm) 200 Upto 600
Upper small intestine
Flow rate (mL/min) 0.6–1.2 2.0–4.2
pH 5.5–6.5 5.5–6.5
Bile acids (mmol/L) 4-6 10–40
Ionic strength 0.16 0.16
Please cite this article as: Shekhawat Prachi, Pokharkar Varsha. Understanding
tackling solubility and permeability hurdles. Acta Pharmaceutica Sinica B (3. Reciprocity between factors affecting drug absorption
The journey of drug through the GI tract as discussed suggests that
the successful development of a dosage form depends upon
complex functions such as dissolution, intestinal permeability,
cellular permeability, binding to plasma proteins, drug distribution,
metabolism and disposition. Pharmacokinetic failure of lead
candidates occurs because of a combination of one or more factors
such as physicochemical properties of drug, physiological barriers
or dosage form design which affect solubility and absorption.
Physicochemical properties of a drug such as lipophilicity and
solubility are the key properties which are affected by molecular
weight, melting point, H-bonding, pKa, molecular shape and
amphiphilicity34. The pioneer and worldwide-accepted qualitative
predictive tool is Lipinski's ‘rule of ﬁve’ introduced by Christopher
Lipinski35 in the 1990s which is the computational ﬁlter for rapid
evaluation of drug properties. It states that a molecule would be
most likely to have poor absorption if it satisﬁes any two of the
following criteria36-38: a molecular weight (MW) 4 500 Da, an
octanol–water partition coefﬁcient (clogP)45 or MlogP4 4.15,
the number of H-bond donors is 4 5 and the number of H-bond
acceptors is 4 10. Molecular weight of the compound should be
less than 500, preferably uncharged (unionized form) and fairly
lipophilic so as to cross the intestinal epithelium passively. A
highly lipophilic molecule will stick to membranes and will not
cross the intestinal barrier. Though the ‘rule of ﬁve’ is an effective
tool in early development, it has a particular limitation in that it
only holds for molecules which are not substrates of active
transporters. In addition to the molecular properties discussed by
Lipinski, other properties discussed below are also very important.
A simple measure of hydrogen binding capacity (hydrogen bond
donors or acceptor) is the polar surface area, deﬁned as the area
occupied by nitrogen, oxygen and hydrogen atoms attached to
these heteroatoms. Palm et al.39 used dynamic polar surface area
(PSAd) to predict poorly absorbed drugs at an early stage of
research and development. They found a good correlation
(r2¼0.94) between PSA and fraction absorbed for 20 drugs and
revealed that drug with PSAd 4140 will show poor absorption
(o10%) while PSAdo60 yields good absorption (4 90%). Clark
et al.40 studied the relationship of PSA with intestinal absorption
considering only single conformer, suggested that a poorlyFigure 2 BCS classiﬁcation and IVIVC expectation for immediate
release dosage form54.
peroral absorption: Regulatory aspects and contemporary approaches to
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Table 4 Analytical tools to access solubility57,58.
Analytical
method
Solubility
determination
technique
Advantage Disadvantage
Light scattering
or turbidity
Kinetic solubility Universal, fast, economical Interference from certain colored compounds and
impurities, sensitive to sedimentation and
particle size, low sensitivity, measures
precipitates rather than solution concentration
UV plate reader Equilibrium or
saturation solubility
High sample coverage, fast, economical,
sufﬁcient sensitivity for solubility measurement,
good linearity over wide dynamic range
Require UV chromophore, interference from
impurities and matrix material
LC-UV Equilibrium or semi-
equilibrium solubility
High sample coverage, less interference from
impurities and matrix material, sufﬁcient
sensitivity for solubility measurement, good
linearity over dynamic range
Requires UV chromophore, might need different
HPLC method for special compounds, not as fast
and economical as UV method
LC-MS Equilibrium or semi-
equilibrium solubility
High sensitivity, high selectivity, low
interference
Less universal, moderate sample coverage, low
dynamic range of linearity, too sensitive to
solubility measurement, high maintenance,
costly
Understanding peroral absorption: regulatory aspects and contemporary approaches 7absorbed molecule will have PSA4140Âe. Daniel et al.41 assessed
molecular properties such as polar surface area, hydrogen bond
count and number of rotational bond as a simple measures of
molecular ﬂexibility for over 1100 drug candidates studied at
GlaxoSmithKline and they reported that about 65% of the
compounds with seven or fewer rotational bonds have oral
bioavailability (F, %) of 20% or more in rats, independent of
molecular weight while 75% compounds with more than 10
rotational bonds show oral bioavailability less than 20%. The
fewer the number of aromatic rings in the lead molecule, the more
chances of it showing good a pharmacokinetic proﬁle. More than
three aromatic rings in a molecule relates to a poor pharmacoki-
netic proﬁle and more chances of failure in drug development.
Aromatic heterocycles will have a lesser effect on increasing
lipophilicity than carbon-containing aromatics but will increase the
PSA which might reduce oral absorption42. Understanding the
physicochemical properties of a drug are very important for the
successful development of a drug candidate. Several efforts have
been carried out to predict the favorable performance of a
molecule for drug absorption depending on physicochemical
properties. Dressman et al.43 developed an absorption potential
(AP) model based on readily available physicochemical property
data which could be determined at an earlier phase of drug
development and thus provide an excellent tool for initial
prediction of absorption, as shown in Eq. (3):
AP¼ PFnon
S0VL
X0
ð3Þ
where P is octanol–water partition coefﬁcient, Fnon is the fraction in
nonionised form at pH 6.5, S0 is intrinsic solubility, VL is volume of
the luminal contents and X0 is the dose administered. Similarly,
Yalkowsky et al.44 expressed absorption parameter π based on
physicochemical properties like aqueous solubility, Cs, melting point
and the octanol–water partition coefﬁcient. Anatomical and physio-
logical conditions like gastrointestinal pH, surface area for absorption,
fed and fasted condition, gastric transit, disease state, age, sex also
affect the pharmacokinetic behavior45,46. It is widely accepted fact
that the nonionized form of a drug is better absorbed than the ionized
form. The unionized form of a drug depends upon the dissociation
constant of the drug in the physiological pH range. GI pH changesPlease cite this article as: Shekhawat Prachi, Pokharkar Varsha. Understanding
tackling solubility and permeability hurdles. Acta Pharmaceutica Sinica B (depending upon the fed or fasted state. In the fasted-state stomach the
pH ranges from 1 to 3, duodenum 5–6, and around pH 6–7 in the
jejunum and ileum while, in the fed-state stomach the pH ranges in
between 4 and 5, 4.5–5.5 in duodenum and 6.5–7.5 in jejunum and
ileum. Maximum absorption of drug occurs in jejunum and ileum
within 3–5 h, in pH range of 4.5–8 which suggests that weak acids
are better absorbed in jejunum while weak bases are better absorbed
in the ileum47. Table 3 lists some important variables of fed- and
fasted-state conditions. When drug is given orally, the absorption
window exists within the GI tract in which drug is efﬁciently
absorbed, and thus gastrointestinal motility and transit time affects
absorption. The small intestine is generally regarded as a main site for
absorption and hence contact time of drug with small intestinal
mucosa will be a key determinant especially for drugs having low
permeability, those transported by a carrier-mediated pathway or
subjected to intestinal degradation, and for drugs having poor
dissolution. Gastric emptying rate also plays an important role in
absorption after oral drug administration which is affected by various
factors such as intake of ﬂuid volume, pH, and size and density of
drug particles. The GI transit and absorption (GITA) model analyzes
absorption kinetics of drugs with variable absorption characteristics
and shows the importance of GI transit rate in determining the
bioavailability of orally administered drugs48. Fujioka et al.49 have
predicted the mean plasma concentration time proﬁle of griseofulvin
using the GITA model and concluded that longer residence time
could lead to higher dissolution and absorption, thus variance in
intestinal transit may be responsible for inter-individual differences
in vivo. We also reported that gastric emptying rate was not
signiﬁcantly correlated with the absorption and dissolution behavior
of griseofulvin. The other important factor responsible for poor
bioavailability is the formulation-related factor. Formulation factors
include types of excipients (lubricant, glidant, bulking agent, solubi-
lizing agent), formulation process (dry granulation and wet granula-
tion, etc.), and particle size.4. BCS
Solubility and permeability interactions and their impact on
intestinal drug absorption are most prominently described by theperoral absorption: Regulatory aspects and contemporary approaches to
2016), http://dx.doi.org/10.1016/j.apsb.2016.09.005
Table 5 Limits of drug dissolution on solubility to avoid absorption problem33,59.
Factor Limit
Solubility in pH 1–7 410 mg/mL at all pH
Solubility in pH 1–8
and dose
Complete dose dissolved in 250 mL
at all pH
Water solubility 40.1 mg/mL
Dissolution rate in pH
1–7
41 mg/min cm2 (0.1–1 mg/min cm2
borderline) at all pH
Prachi Shekhawat, Varsha Pokharkar8BCS framed by Amidon et al.11 on the basis of dimensionless
numbers. BCS provides drug designers with an opportunity to
manipulate the structure or physicochemical properties of lead
candidates to achieve better “deliverability”. BCS classiﬁcation is
extensively used by the pharmaceutical companies throughout
drug discovery and development and can also help companies save
development time and reduce costs50,51. This system has been
adopted by US Food and Drug Administration (FDA), the
European Medicines Agency (EMEA) and World Health Organi-
zation (WHO) for setting bioavailability/bioequivalence (BA/BE)
standards for immediate-release oral drug product approvals52.
BCS principles are also included in ICH guidelines for require-
ments of in vitro dissolution testing as a quality control in
manufacturing12.
BCS has classiﬁed API and ﬁnished dosage form on the basis
of simple laboratory test solubility and permeability while
dissolution is the ﬁnal dosage form characteristic. Fundamental
behind the BCS are three dimensionless numbers viz. absorption
number (An), dissolution number (Dn) and dose number (Do)
which predicts the fraction dose absorbed in humans based on
physicochemical and physiological factors. An is the ratio of
radial absorption rate to axial convection rate. An An value larger
than 1 suggests complete absorption. Dissolution number refers
to the time required for drug dissolution which is the ratio of the
intestinal residence time to the dissolution time. The higher the
dissolution number the higher will be the fraction-dose absorbed.
Dose number is a criterion for solubility (Do) which is deﬁned as
the ratio of dose concentration to drug solubility. A dose number
equal to or lower than 1 indicates high solubility and Do 4
1 signiﬁes low solubility53.
Drugs are classiﬁed as highly soluble and highly permeable
(Class I) if they are well absorbed (although systemic availability
may be low due to ﬁrst-pass metabolism), do not have narrow
therapeutic index, and dissolution of485% ino15 min predicts
complete absorption. These candidates may qualify for biowaiver
of very expensive BA/BE studies. Class I drugs have a high
absorption number (An41.15) and a high dissolution number
(Dn41). For drugs having low solubility and high permeability
(Class II), the rate-limiting step in absorption is poor solubility.
Hence, a correlation between the in vivo bioavailability and the
in vitro solvation can be found. Nonpolar characteristics of a
drug are responsible for poor solubility and thus have a higher
absorption number. The dissolution rate of water-insoluble
compounds is low (Dno1) while An and Do are high for many
class II drugs. Class III compounds are highly soluble with low
permeability where the rate-controlling step is absorption while
the drug gets solvated very quickly and there is always risk of
being excreted without showing any physiological effect. Class
IV drugs are compounds which suffer from poor bioavailability
and high variability because of low solubility and lowPlease cite this article as: Shekhawat Prachi, Pokharkar Varsha. Understanding
tackling solubility and permeability hurdles. Acta Pharmaceutica Sinica B (permeability. These compounds have lower An and Dn number.
Class IV compounds are rarely developed and marketed. Never-
theless, several Class IV drugs do exist. The BCS classes along
with in-vitro–in-vivo correlation expectation for immediate
release expectation are shown in Fig. 254.4.1. Solubility boundaries
BCS deﬁnes the API as being “highly soluble” when the highest
recommended dose is soluble in 250 mL or less of aqueous media
over the pH range of 1.2 to 7.5. A volume of 250 mL of aqueous
media is taken to mimic the in vivo condition as same amount is
present in upper GI tract when administering drug in the fasted
state. Solubility is the amount of a substance that has passed into
solution when equilibrium is attained between the solution and
excess substance at a given temperature and pressure. The BCS
solubility deﬁnition includes the highest dose strength in volume
of 250 mL where dose/solubility (D:S)o250 refers highly soluble
drugs but cannot be extended to pediatric patients as the volume
does not hold true. Attempts are being carried out to extend the
BCS to pediatric BCS55. Various solubility determination methods
have been developed to assess solubility at various stages of drug
discovery and development. These solubility protocols have been
studied such that they are close to the actual solubilization process.
Kinetic solubility, semi-equilibrium and the equilibrium solubility
method have been developed over the past several years. When
determining solubility by the kinetic approach, the drug is in a
predissolved state in DMSO and precipitated in aqueous buffer
with typical pH 6.5 (intestine) or pH 7.4 (bioassay or blood).
Precipitation is detected optically and kinetic solubility is the
concentration preceding precipitation. A rule of thumb is to keep
the amount of DMSO typically r1% to prevent the potential
cosolvency effect. Precipitate thus formed can either be removed
or can be used as an indicator for direct measuring by nephel-
ometer through light scattering signals or increased UV absor-
bance due to particle blocking the light from reaching the detector.
When ﬁltering the solution for assay, selection of the proper ﬁlter
membrane is critical as it shows non-speciﬁc drug absorption.
Hydrophillic PVDF ﬁlters are most suitable and nylon ﬁlters are
not recommended. Another more recent method is dried DMSO or
the semi-equilibrium method which subsequently removes DMSO
by evaporation thus leaving solid-like material prior to addition of
buffer to determine solubility56. Such solubility protocols provide
rapid throughput screening, rapid availability of results, are
efﬁcient in terms of workload and use API in milligram quantities,
thus saving 80% of time compared with the traditional shake-ﬂask
method. Though having mentioned these positive attributes ques-
tions should be raised as to whether such protocols misguide the
chemist during lead optimization. It has been shown toperoral absorption: Regulatory aspects and contemporary approaches to
2016), http://dx.doi.org/10.1016/j.apsb.2016.09.005
Understanding peroral absorption: regulatory aspects and contemporary approaches 9overestimate the solubility when compared to thermodynamic
solubility. Thus the value of such techniques are stage-dependent
and cannot replace thermodynamic solubility studies which are
usually performed at latter stages of discovery57. Thermodynamic
solubility, in contrast, is performed by dispersing an excess of
powdered drug into a liquid (buffer or water) and is assayed after
equilibrium is established. It usually takes 24–48 h to establish
equilibrium. To conﬁrm that equilibrium has been achieved,
compound solubility has to be constant with time, and hence
solubility measurements at several points are necessary. To over-
come the disadvantages with conventional shake-ﬂask method, a
novel miniaturized shake-ﬂask solubility method streamlined with
HPLC analysis has been validated and optimized via test set of 85
marketed drugs and Novartis internal compounds58. Different
analytical tools used for detection are discussed in Table 4.4.2. Dissolution boundaries
A drug product is considered to be “rapidly dissolving” when4 85%
of the labeled amount of drug substance dissolves within 30 min using
USP apparatus I or II in a volume of o900 mL buffer solutions. As
discussed above, the dissolution study is the basis for BCS classiﬁca-
tion and used to predict the performance of formulations in the
gastrointestinal tract (in vivo). The dissolution study is the predictive
tool for bioavailability and in vitro–in vivo correlation (IVIVC).
Proposed criteria to be used to avoid absorption problems caused by
poor dissolution are given in Table 533,59. Choosing the dissolution
system parameter like media, stirring rate, temperature, instrument is
based on considerations such as where in the GI tract is drug released
from the dosage form, how long the dosage should release the drug
and the composition of the ﬂuid. Ideally, physiological conditions
should be taken into consideration when choosing the in vitro test
condition. Dissolution media listed in USP are dilute hydrochloric
acid, USP simulated gastric ﬂuid without enzymes (a pH 4.5 buffer;
and a pH 6.8 buffer), simulated intestinal ﬂuid USP without enzymes
and surfactant solutions containing polysorbate 80 and sodium lauryl
sulphate. These media simulate the osmolarity and pH effect of drug
release while surfactant solution increases the solubility of drugs in
aqueous media. These media are easily reproducible and routinely
used in QC protocols but may not be useful for BCS class II or IV
drugs. For such compounds dissolution is rate the limiting step for
absorption thus the prediction of in vivo behavior should be based on a
well designed in vitro test mimicking the in vivo conditions using
biorelevant media. Simulating the in vivo condition using biorelevant
media has been used to increase the in vivo predictability60,61. The
International Pharmaceutical Federation (FIP) guidelines published
two complex media including a fasted state simulated intestinal ﬂuid
(FaSSIF) and fed state simulated intestinal ﬂuid (FeSSIF) which
contain the most important physiological amphiphiles, bile salt and
lecithin, having pH, buffer capacity and osmolarity of the gut lumen62.
Wei et al.63 studied dissolution behavior of glyburide BCS class II
drug in apparatus II with various dissolution media FaSSIF, simulated
intestinal ﬂuid (SIF) and blank FaSSIF without lecithin and taur-
ocholate (BL-FaSSIF) with constant and dynamic pH conditions (5.0
to 7.5). The change in pH simulates the physiological change in the
small intestine and large intestine. Results revealed that micellization
prevents glyburide from precipitation despite unfavorable pH and thus
concluded that biorelevant media (FaSSIF) are suitable for studying
the dissolution rate of BCS class II drugs. Biorelevant media are useful
in predicting IVIVC for class II drugs but the complexity and cost has
limited its extensive use for industrial applications. Lehto et al.64Please cite this article as: Shekhawat Prachi, Pokharkar Varsha. Understanding
tackling solubility and permeability hurdles. Acta Pharmaceutica Sinica B (studied the dissolution behavior of N74 (BCS class II drug) in
biorelevant simple conventional surfactant media containing various
concentrations of anionic surfactant, sodium lauryl sulphate and non
ionic surfactant polysorbate 80 (Tween) which easily replaced bile
salt/lecithin mixture owing to its similar wetting and solubilization
behavior. They concluded that the potential of substituting FaSSIF
with more simple and cost effective conventional surfactant media
which could largely assist in industrial drug development and quality
control purposes was possible. Several efforts have also been carried
out to mimic the in vivo condition. A novel dissolution apparatus
known as a gastrointestinal simulator (GIS) has the potential to be a
standard biopredictive tool for in vitro dissolution testing, and consists
of three dissolution chambers representing stomach, duodenum and
early jejunum chambers. The ﬂuid transit time between those
chambers can be adjusted in the range of 1–40 mL/min by peristaltic
pumps. Authors have studied the dissolution proﬁle for BCS class II
drugs such as pioglitazone and ketoconazole by using GIS system and
concluded that buffer capacity, buffer species and pH of the medium
have a signiﬁcant effect on dissolution rate of pioglitazone and
ketoconazole65. Similarly, Motz et al.66 have attempted to develop a
novel apparatus containing a ﬂow-through dissolution cell (USP
apparatus 4) connected with a Caco-2 permeation cell to assess
intestinal permeability of drugs containing a solid dosage form.
Intrinsic dissolution rate is generally deﬁned as the dissolution rate
of a pure drug substance under the condition of constant surface area,
agitation or stirring speed, pH and ionic strength of the dissolution
medium. Milani et al.67 have studied intrinsic dissolution rate (IDR)
and rat intestinal permeability (using SPIP technique) for drugs with
different physicochemical properties to evaluate suitability in BCS.
Muenster et al.68 have used apparent dissolution rate and volume to
dissolve applied dose (VDAD) as a tool to predict in vivo performance
of a drug contributing to a successful drug development candidate.4.3. Permeability boundaries
BCS deﬁnes drug substance as “highly permeable” when the
extent of absorption in humans is greater than 90% of an
administered dose, based on mass-balance or compared with an
intravenous reference dose. Drug is transported through the
intestinal barrier via passive diffusion or other parallel transport
mechanisms and thus controls effective permeability (Peff) of the
drug. Effective permeability (Peff) is generally described in terms
of units of molecular movement distance per unit time (e.g.,
104 cm/s). The drugs with jejunal Peff41.5 104 are comple-
tely absorbed independent of transport mechanism69. The FDA
BCS guideline describes various methods to predict drug perme-
ability through GI tract. Permeability data is considered valid if it
is obtained from in vivo human trials (mass balance pharmacoki-
netic studies, absolute bioavailability studies, intestinal perfusion
methods). Apart from the human trials, in situ permeability studies
(e.g., rat intestine), in vivo permeability studies in animal and
in vitro permeability studies such as in epithelial cell monolayers,
e.g. Caco-2, provide supportive data for permeation70. Drugs with
an apparent permeability (Papp) value less than 1 106 cm/s are
poorly absorbed (0–20% absorbed), drugs with Papp value between
1 and 10 106 cm/s are moderately absorbed (20%–70%
absorbed) and drugs with Papp value between 10 106 cm/s
are well absorbed (70%–100% absorbed)71. Wahlang et al.72
assessed the permeability of curcumin using Caco-2 cell mono-
layers. Curcumin was found to be poorly permeable across the
Caco-2 cell monolayer. Poor solubility and poor permeabilityperoral absorption: Regulatory aspects and contemporary approaches to
2016), http://dx.doi.org/10.1016/j.apsb.2016.09.005
Prachi Shekhawat, Varsha Pokharkar10places curcumin into class IV which helps in designing a drug
delivery system for poorly bioavailable molecules.
BCS classiﬁcation provides a tool to skip the in vivo bioequiva-
lence studies by a simple in vitro dissolution test. In fact for
immediate release (IR) solid dosage form which contains rapid
dissolving and easily permeating API (BCS class I), bioequivalence
studies may not be required because these drugs or drug products
behave as a simple solution which is readily absorbed. If two drug
products contain same API having similar GI concentration–time
under all luminal conditions, then a similar rate and extent of
absorption is ensured for these products. Thus, bioequivalence (BE)
can be guaranteed based on in vitro dissolution tests rather than
doing empirical in vivo human trials. Initially, waivers of in vivo
bioequivalence were accepted only for Scale-up and Post Approval
Changes (SUPAC) but later were extended to approval of new
generic drug products, thereby avoiding the cost of human trials and
reducing the cost to develop the generic product. Such a tool
shortens the drug development period, economizes the resources
and leads to improved product quality. According to the FDA
guidance for the industry ‘Waiver of in vivo bioavailability and
bioequivalence studies for immediate-release solid oral dosage
forms based on a Biopharmaceutics Classiﬁcation System’, a
biowaiver can currently be requested only for solid, orally adminis-
tered immediate-release products (485% release in 30 min), con-
taining drugs with a high solubility over the pH range from 1 to 7.5
(D:S o250 mL) and high permeability (fraction absorbed
490%)73. It has also been recommended that biowaiver can also
be extended to BCS class III drugs as these behave in vivo like an
oral solution and thus their bioavailability would be dependent on
gastric emptying rather than on drug product properties. Thus
emphasis should be made on an excipient which modiﬁes GI transit
(e.g., sugar alcohols) or drug absorption74. BCS can also be used as
a signal tool for need of formulation design (for BCS class II, III
and IV drugs). Despite its simplicity, BCS has various complexities
in the evaluation and investigation of in vitro and in vivo
performance of a drug or drug product. Hence, continuous reﬁne-
ments are being done to develop a more science-based mechanistic
tool. Recently, Tsume et al.75 subclassiﬁed class II and class IV
drugs depending upon acidic (a), basic (b) and neutral
(c) characteristics in the physiological pH range (pHo7.5) which
can serve as a basis for developing in vivo predictive dissolution and
absorption methodology. BCS has also lead to development of other
systems such as the biopharmaceutical drug disposition system
(BDDS) which is a complimentary system focused on drug
disposition replacing the permeability criteria. Wu et al.76 in 2005
noticed the fact that highly permeable drugs are eliminated via
metabolism while poorly permeable drugs are eliminated unchanged
in bile and urine, leading to the development of this system.
Solubility criteria for both the systems are the same, permeability
has been replaced by route of elimination since it can be determined
based on extent of metabolism easily. BDDS serves as a basis for
predicting the importance of transporters in determining several
pharmacokinetic parameters. BDDS class I compounds are highly
soluble and extensively metabolized. Class I drugs are present in gut
in high concentration to saturate transporter and may be substrates
for either efﬂux or inﬂux transporters. Transporter effects are
minimal and are not clinically important. Class II drugs, being
highly permeable, readily cross the gut membrane and hence inﬂux
transporters are clinically unimportant. Effects of efﬂux transporters
are predominant as these drugs are poorly soluble preventing the
saturation of efﬂux transporter. Class III and Class IV drugs are
highly soluble/poorly metabolized and poorly soluble/poorlyPlease cite this article as: Shekhawat Prachi, Pokharkar Varsha. Understanding
tackling solubility and permeability hurdles. Acta Pharmaceutica Sinica B (metabolized drugs, respectively. Class III compounds suffer from
poor permeability and thus inﬂux transporters play an important role
and their effect is predominant. Efﬂux transporters may also be
important when permeation occurs through absorptive transporters.
Absorptive as well as efﬂux transporters are both important for
absorption of class IV compounds77.5. Formulation approaches for manipulating solubility and
permeability
Despite the number of tools available, there is often a need to
compromise with two fundamental issues during lead optimization
phase, i.e., drug solubility and drug permeability. Knowledge of
BCS can help the formulation scientist to manipulate solubility and
permeability issues. BCS class I drugs do not generally have
bioavailability issues as these behave as simple solution in vivo
and show a very fast increase in blood plasma level. But
sometimes a slower and longer-lasting effect is desired which
can be achieved by using modiﬁed-release dosage forms and
polymer-based formulation approaches. Poor water solubility is
the important criteria for both oral as well as intravenous
administration routes. Almost half of the new molecular entity
(NMEs) synthesized annually by pharmaceutical companies are
poorly water-soluble, which has reduced the performance of 10%
of successfully marketed drugs78. Poorly water-soluble drugs
belong to class II and class IV of the BCS. A candidate being
poorly water-soluble falls in a different class of BCS because of
different physicochemical reasons. Poor solubility may be due to
solvation extreme called as “grease ball” having higher logP and
lower melting point or due to crystal packing interactions called
“brick dust” which has low solubility in lipids but considerable
solubility in surfactant. Various approaches have been used to deal
with poor solubility and poor permeability issues like particle size
reduction79-81, nanoparticulate systems82,83, solid dispersion84,85,
crystal modiﬁcation86,87, host-guest complexation88,89 and lipid-
based drug delivery systems90 are considered the most successful
approaches to improve the rate of dissolution and permeability.
5.1. Nanoparticulate systems
The particle size reduction approach is a widely used technique to
increase the rate of dissolution of poorly water-soluble drug by
increasing the surface area of drug91. Two basic particle size
reduction approaches are micronization and nanonization.
Mechanical pulverization (crushing, grinding and milling) is the
common techniques for preparation of micron size particles. Dry
milling techniques reduce the particle size to 2–5 μm which not
always increases the dissolution rate and sometimes may increase
agglomeration, increasing the surface area. Thus, surfactants and
polymeric materials are needed to prevent particle agglomeration.
Larger particle size can lead to capillary blockage and embolism
with intravenous administration. Reducing the particle size to the
nanorange (o 1000 nm) improves the safety of oral delivery by
increasing the distribution uniformity in the GI ﬂuid and avoiding
high and prolonged local concentrations83. Reduction of particle
size to the nano range increases the dissolution rate by increasing
surface area (A), increasing the concentration gradient (Cs–Cb),
reducing the diffusional layer distance (h) and increasing the
adherence to intestinal membrane92. Reducing the particle size to
less than 1 μm increases the saturation solubility as described by
Ostwald–Freundlich's equation. Nanocrystal and nanosuspensionperoral absorption: Regulatory aspects and contemporary approaches to
2016), http://dx.doi.org/10.1016/j.apsb.2016.09.005
Table 6 Formulation strategies for bioavailability enhancement of poorly water-soluble/absorbable drug.
Formulation
strategy
Technique Drug BCS
Class
Comment Ref.
Microcrystals Antisolvent precipitation Megestrol acetate II Kollidon VA64 and Poloxamer 407 inhibits crystal growth thereby improved dissolution rate in
when compared to unprocessed drug.
99
Microparticles Rapid expansion of supercritical
solution in liquid antisolvent
Fenoﬁbrate II Suspension with high drug load stabilized electrostatically using sodium dodecyl sulphate (SDS). 100
PLGA microparticle Spray drying Nimodipine II PLGA polymeric microparticles with high drug loading suspended in Tisseel ﬁbrin sealent as an
in situ device for the local treatment of vasospasm after subarachnoid hemorrhage.
101
Nanocrystal Supercritical antisolvent method Apigenin II Decreased particle size, smooth surface with spherical shape and no substantial change in
crystallinity of drug.
102
Amorphous
nanoparticle
Controlled Precipitation technique Aprepitant II Nanostructured formulation stabilized by soluplus and SDS as secondary stabilizer having particle
size of less than 100 nm with instantaneous redispersibility. Solubility and PAMPA assay in
agreement with in vivo kinetic studies.
103
pMMA coated
thiolated chitosan
nanoparticle
Radical polymerization Docetaxel II Tenfold increase in oral bioavailability of nanoparticle formulation may be attributed to
mucoadhesion, P-gp efﬂux inhibition and permeability enhancement effect of thiolated chitosan.
104
PEG-b-PLA
nanoparticle
Flash nanoprecipitation Doxorubicin III Overexpression of P-gp in MDR cell contribute low cellular accumulation. Self-assembled PEG-b-
PLA nanoparticle demonstrated higher retention in MDR cell and passive targeting to tumor cell.
105
Nanocrystal Combination technology
(antisolvent precipitation and
microﬂuidization)
Bexarotene II Nanocrystal formulation optimized using L9 orthogonal array stabilized using lecithin and
poloxamer 188 for oral and parenteral delivery.
106
Nanocrystal Antisolvent precipitation Carvedilol II SDS stabilized nanosuspension demonstrated increased Cmax and AUC while decrease in Tmaxwhen
compared with coarse suspension.
107
Nanocrystal Wet media Milling Febuxostat II HPMC and vitamin E TPGS stabilized system with 221.6% increase in relative bioavailability. 108
Nanocrystal Precipitation-high pressure
homogenization method
Nitrendipine II Surface modiﬁed chitosan nanocrystal stabilized with polyvinyl alcohol (PVA) has better stability
and bioavailability compared with unmodiﬁed crystals.
109
Nanocrystal Wet-milling technology Tranilast II Hydroxy propyl cellulose-SL and SDS stabilized redispersible system exhibited improvement in
the dissolution behavior under acidic conditions and enhancing the therapeutic potential of tranilast
to treat liver dysfunction.
110
Solid
nanodispersion
Dry media milling Ingliforib, celecoxib
furosemide
II, IV Novel formulation approach combining two technologies,i.e.,solid dispersion and nanocrystal, and
stabilized with PVP K12 and SDS.
111
Solid dispersion Spray drying technique Tacrolimus II The formulation containing drug–Eudragit E exhibited higher drug solubility as it inhibits
reprecipitation in neutral pH condition.
112
Solid dispersion Lyophillization technique Atorvastatin II Solid dispersion formulation containing skimmed milk as a carrier in varying ratio has shown 33
fold increase in solubility as compared to pure drug and 3-fold increase in lipid lowering potential.
113
Solid dispersion Lyophillization technique TMC-240 (HIV Protease
Inhibitor)
IV Inulin based SD combined with ritonavir to improve permeation through intestinal wall. 114
Solid dispersion Solvent evaporation Pioglitazone II SD prepared by amorphous polymer (PVP K30 and PVP K90) and semicrystalline polymer (PEG
6000 and F68). Further concluding amorphous polymer being more suitable as it is more effective
at inhibiting crystallization rates.
115
Solid dispersion Wet milling followed by freeze
drying
Tranilast II Nanocrystal TL-loaded SD formulation containing HPC-SL and SDS was found to have better
dissolution and pharmacokinetic behaviors and thus bioavailability with high photochemical
stability.
116
U
nderstanding
peroral
absorption:
regulatory
aspects
and
contem
porary
approaches
11
P
lease
cite
this
article
as:
S
hekhaw
at
P
rachi,P
okharkar
V
arsha.U
nderstanding
peroral
absorption:
R
egulatory
aspects
and
contem
porary
approaches
to
tackling
solubility
and
perm
eability
hurdles.
A
cta
P
h
a
rm
a
ceu
tica
S
in
ica
B
(2
0
1
6
),
h
ttp
://d
x
.d
o
i.o
rg
/1
0
.1
0
1
6
/j.a
p
sb
.2
0
1
6
.0
9
.0
0
5
Table 6 (continued )
Formulation
strategy
Technique Drug BCS
Class
Comment Ref.
Cyclodextrin
complexation
Lyophillization technique Acetazolamide IV Amorphous HP-β-CD/drug complex prepared with and without triethanolamine (salt formation
signiﬁcantly increased the HP-β-CD solubilizing power) shows enhanced dissolution rate thus
improving intraocular pressure lowering effect.
117
Cyclodextrin
complexation
Blending, co-grinding, kneading,
coevaporation
Clonazepam II Co-grinded product with methylated-β -CD was found to be best carrier for improving the
solubility and dissolution rate of drug.
118
Cyclodextrin
complexation
Kneading method Ibuprofen II Tablet (direct compression) and pellet (extrusion/spheronization) formulated by drug/β-CD
complex have shown high solubility and dissolution rate when compared with reference and
marketed formulation.
119
SNEDDS Vortexing Lurasidone II SNEDDS prepared using Capmul MCM, Tween 80 and glycerol as oil phase, surfactant and co-
surfactant system respectively with enhanced oral bioavailability with no food effect.
120
SMEDDS Vortexing Puerarin II SMEDDS containing castor oil (oil), cremophore EL (emulsiﬁer) and 1,2-propanediol (co-
emulsiﬁer) was pelletised via extrusion-spheronization technique to form SMEDDS sustained
release pellets.
121
SNEDDS Vortexing Cinnarazine II SNEDDS containing sesame oil (oil phase), cremophore RH40 (surfactant), oleic acid (surfactant)
and brij 97 (co-surfactant). Food effect on cinnarazine could be signiﬁcantly reduced by dosing
either as SNEDDS capsule or tablet.
122
SNEDDS Pre-concentrate preparation
method
Amiodarone and talinolol II SNEDDS resulted in higher and less variable AUC and Tmax. SNEDDS increases the solubilization,
reduces intraenterocyte metabolism, reduced P-gp efﬂux and does not cause intestinal tissue
damage.
123
SNEDDS Vortexing Cefpodoxime proxetil IV SNEDDS containing campul MCM (oil), Tween 80 as surfactant, TPGS as co surfactant which was
further pelletised has shown to improve solubilization which improves the permeability by 10-fold
and bioavailability by 4-fold.
124
SNEDDS Vortexing Valsartan II Solid-SNEDDS system was prepared containing campul MCM (oil), labrasol (surfactant) and
Tween 20 (co-surfactant) SNEDDS adsorbed on the solid carrier (Sylysia 350) and compressed into
tablet. The system has shown 3.5-fold increase in dissolution rate of drug due to enhanced
solubility.
125
SNEDDS Vortexing Ziprasidone II SNEDDS prepared using campul MCM (oil phase), labrasol (surfactant) and PEG 400 (co
surfactant) which was further used to prepare sustained release pellets showed prolonged action
with enhanced bioavailability.
126
SMEDDS Vortexing Pioglitazone II SMEDDS prepared using cottonseed oil, Tween 80 as surfactant and PEG as co-surfactant has been
used to improve rate of dissolution of pioglitazone 2- to 3-fold when compared with commercial
tablet.
127
SMEDDS Vortexing Furesemide IV SMEDDS was developed using oleic acid based heterolipid as oil phase, solutol HS 15 as
surfactant and ethanol as co surfactant. It signiﬁcantly improved solubility of furesemide as
compared to parent oil, oliec acid.
128
SMEDDS Vortexing Baicalein II SMEDDS formulation containing capryliccapric triglyceride, cremophor RH40 and transcutol P
has shown signiﬁcantly higher release rate and 200.7% increase in relative bioavailability
compared with that of the baicalein suspension.
129
SLN Hot emulsiﬁcation/ solidiﬁcation
method
Paclitaxel IV SLN prepared by hot homogenization technique as a carrier showed higher cellular uptake
demonstrating higher efﬁcacy in cancer cell death.
130
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NLC Melt emulsiﬁcation
homogenization
Montelukast II NLC prepared using precirol ATO-5 and capryol-90 and D,L-pyrolidonecarboxylic acid salt of
L-cocyl arginine ethyl ester surfactant showed 143-fold improvement in bioavailability.
131
NLC High pressure homogenization Saquinavir IV Three NLC based formulation containing precirol ATO5, miglyol 812 as lipid phase and different
concentration of poloxamer 188 and Tween 80 as aqueous phase. NLC enhanced SQV
permeability and circumvented P-gp efﬂux.
132
Mesoporous silica
(SBA-15)
– Fenoﬁbrate II Drug-silica formulation has shown signiﬁcant increase in dissolution rate when compared with
micronized fenoﬁbrate which was attributed to high surface area and decreased in crystallinity of
drug after absorption onto silica.
133
Mesoporous silica
MCM-41
– Furesemide IV Drug inclusion into MCM-41 mesoporous displayed enhancement in dissolution rate with complete
release in 90 min and enhanced photochemical stability.
134
Mesoporous silica
MCM-41
– Piroxicam II Inclusion of poor soluble drug in MCM-41 improved the dissolution rate due to lack of crystallinity
and extremely high surface area of siliceous material.
135
Mesoporous silica – Itraconazole II Itraconazole loaded into ordered mesoporous silica have shown signiﬁcantly improved AUC,
decreased Tmax. OMS formulation compares well with the marketed product (sporanox) thus
considered as better carrier.
136
Porous silicon based
microparticles
– Antipyrene, ibuprofen,
griseofulvin, ranitidine,
furosemide
II, IV Drug loaded in mesoporous silicon microparticle increased the dissolution rate and reduced the pH
dependency dissolution.
137
Micelle Thin ﬁlm hydration Amphotericin II Self-assembled lecithin-based mixed polymeric micelle containing pluronic, kolliphor RH40,TPGS
and DSPE-PEG2K showed 2.18- and 1.50-fold increased in bioavailability when administered i.v.
and orally.
138
Micelle Dialysis method Paclitaxel IV Pluronic F127, P188 and heparin-all-trans-retinoid acid conjugate mixed micelle exhibited higher
AUC, Cmax and 5- to 6-fold increase in effective permeability.
139
Co-crystal – Quercetin II Quercetin–caffeine, quercetin–caffeine–methanol, quercetin–isonicotinamide and quercetin–
theobromine dihydrate co-crystals exhibited pharmacokinetic properties that are vastly superior
than quercetin alone.
140
Co-crystal Anti-solvent crystallization Indomethacin II Saccharine-indomethacin cocrystals were hygroscopic and found to have signiﬁcantly higher
dissolution rate than pure indomethacin.
141
Co-crystal Anti-solvent crystallization Diﬂunisal II Nicotinamide–diﬂunisal cocrystal improves intrinsic dissolution rate by 20%. 142
Co-crystal Anti-solvent crystallization Ibuprofen II Highly soluble molecule in crystallographic pattern of ibuprofen enhances the solubility more than
7.5 times.
143
Co-crystal Anti-solvent crystallization Ezetimibe II Benzoic acid and salicylic acid ezetimibe co-crystal showed signiﬁcant enhancement in the
dissolution proﬁle as compared to pure ezetimibe.
144
Dendrimer – Camptothecin II G.4 and G.3.5 PAMAM dendrimer increased camptothecin solubilization in simulated gastric ﬂuid
and caused 2-fold to 3-fold increase in oral absorption suggested increased bioavailability.
145
Dendrimer – Famotidine, indomethacin,
amphotericin
II G.5 PPI dendrimer–drug complex demonstrated increase in solubility due to hydrophobic and
electrostatic interactions for acidic, basic and amphoteric drug.
146
Dendrimer – Ketoprofen II PAMAM dendrimer was found to improve solubility of ketoprofen. Solubility of ketoprofen was
found to be proportional to dendrimer concentration.
147
–not applicable.
U
nderstanding
peroral
absorption:
regulatory
aspects
and
contem
porary
approaches
13
P
lease
cite
this
article
as:
S
hekhaw
at
P
rachi,P
okharkar
V
arsha.U
nderstanding
peroral
absorption:
R
egulatory
aspects
and
contem
porary
approaches
to
tackling
solubility
and
perm
eability
hurdles.
A
cta
P
h
a
rm
a
ceu
tica
S
in
ica
B
(2
0
1
6
),
h
ttp
://d
x
.d
o
i.o
rg
/1
0
.1
0
1
6
/j.a
p
sb
.2
0
1
6
.0
9
.0
0
5
Prachi Shekhawat, Varsha Pokharkar14technology can be applied to both BCS class II and class IV drugs.
Nanocrystal formulation can be prepared by two methods, i.e., top-
down technique (wet milling, high pressure homogenization) and
bottom up technique (controlled precipitation). Basically, the top
down method is an attrition method where larger crystals (μm) are
turned to smaller ones (nm). Hydrophillic polymer or surfactants
systems are required to stabilize the nanoparticles. Stabilizer must
be capable of wetting the surface of drug nanocrystal thus
providing steric and ionic stabilization. Stable nano systems can
be obtained when the weight ratio of the drug to stabilizer is 20:1
to 2:1. For increasing the intestinal adhesion surface modiﬁcation
of nanoparticles may be required by using mucoadhesive poly-
mers, as cationic polymers adhere to negative surface of mucin of
gastric mucosa93. Surface modiﬁcation of paclitaxel nanocrystals
using synthesized pluronic grafted chitosan copolymer has shown
to improve relative bioavailability by modulating intestinal P-gp
efﬂux system94. Similarly, surfactant, like vitamin E tocopherol
polyethylene glycol succinate (vit. E TPGS), has also been used to
circumvent P-gp mediated drug efﬂux mechanism95.
Polymeric nanoparticles are also frequently used to improve the
therapeutic value of BCS class II and class IV drugs. The most
commonly used polymers include synthetic polymers like poly-
ethylene glycol (PEG), N-(2-hydroxypropyl)methacrylamide
(HPMA), poly(vinyl pyrrolidone) (PVP), polyethyleneimine (PEI);
pseudosynthetic biodegradable polymers like poly-ɛ-caprolactone,
poly amino acids, poly(lactic acid) (PLA), polyglycolic acid (PGA)
and their copolymers, poly-D,L-lactide-co-glycoside (PLGA); and
natural polymers like chitosan, dextrin and hyaluronic acid. The API
molecule can be either conjugated onto the polymeric material or
can be protected and encapsulated inside the core. These polymeric
nanosystems provide controlled or sustained release, prolong
residence time, reduce nonspeciﬁc distribution and provide protec-
tion against proteolytic enzymes and can improve oral bioavail-
ability. Different polymers can be used for preparation of
nanoparticles with distinctive surface properties, which will strongly
affect structure, properties and biological applications. For example,
nanoparticulate systems synthesized using PLGA, polymethacry-
lates and PEG are considered to be promising delivery systems due
to their mucoadhesive properties which drive various interaction
forces between nanoparticle and mucus membrane such as hydrogen
bonding, van der Waal forces, polymer chain interpenetration,
hydrophobic forces and electrostatic/ionic interactions96. PLGA
nanoparticles were surface modiﬁed using chitosan, vitamin E
TPGS, lecithin and Eudragit RS. An ex vivo mucoadhesive study
and Caco-2 uptake study revealed enhanced mucoadhesion and cell
internalization for chitosan-modiﬁed PLGA nanoparticles. This may
be due to electrostatic interactions between the positively charged
surface of the nanoparticle and negatively charged mucin97.
Andrographolide-loaded pH-sensitive nanoparticles prepared by
using cationic poly-methacrylate copolymer have been shown to
improve bioavailability98. The poly(methacrylic acid and methacry-
late) copolymer allows release of load at a speciﬁc pH within the
gastrointestinal tract. Table 699–147 reveals a few examples of
nanoparticulate systems which improve bioavailability.5.2. Lipid-based drug delivery systems and solid lipid-based
drug delivery systems
Lipid based drug delivery system (LBDDS) has shown a great
promise to deliver poorly soluble and poorly permeable candidates
and appear to be a “one key ﬁts all” system as it strikes all rate-Please cite this article as: Shekhawat Prachi, Pokharkar Varsha. Understanding
tackling solubility and permeability hurdles. Acta Pharmaceutica Sinica B (limiting steps to absorption. Oral bioavailability of water-insoluble
lipophilic drug may be enhanced when it is co-administered with a
fat-rich meal which has lead to realization of lipids as a means to
enhance solubilization in the gastrointestinal tract. Lipid-based
formulations have a positive inﬂuence on drug absorption by
increasing solubilization capacity, preventing drug precipitation on
intestinal dilution, enhancing membrane permeability, inhibiting
efﬂux transporters, reducing CYP enzymes, stimulating secretion
of chylomicrons and improving lymphatic transport148,149. These
are a diverse group of formulations sharing some common
features. They are categorized into ﬁve classes by Colin Pouton150
which includes excipients like triglycerides, mono- and diglycer-
ides, water-insoluble surfactants, water-soluble surfactants and
cosolvents as shown in Table 7150 along with their key features.
Proper screening of excipients and logical design of formulations
is important as LBDDS involves many complex biological
processes like digestion of lipid excipients, formation of different
colloid phases during lipid digestion, inhibition of efﬂux systems.
Lipid colloidal drug delivery systems like liposomes, niosomes,
solid lipid nanoparticles (SLN) and nanostructured lipid carriers
(NLC) are also widely used to enhance bioavailability and also
provide controlled release of active compound151,152. These
nanostructures are widely used due to their versatility, biocompat-
ibility and low cytotoxicity. Liposomes are self-assembled sphe-
rical vesicles consisting of one or several concentric phospholipid
bilayer with an aqueous core inside. Despite great interest in drug
delivery, this system is associated with problems like poorer
entrapment efﬁciency, expense, and physicochemical instability
due to phospholipid hydrolysis or oxidation. An alternative to such
technical difﬁculties is niosome; self-assembled structures consist-
ing of nonionic surfactants of alkyl or dialkyl polyglycerol ether
class with cholesterol. Although structure, properties and in vivo
performance of liposomes and niosomes are similar, they bypass
disadvantages like chemical instability and cost, thus making them
suitable for industrial manufacturing153. In the early 1990s, SLN
were developed as an alternative system to liposome and noisome
with clear advantages of great kinetic stability, rigid morphology
thus capable of modulating drug release, and good production
scalability with wide potential applications. SLN are nanospheres
made from solid lipid with a mean diameter between 50–1000 nm,
while NLC are next generation lipidic carriers with a mixture of
solid–lipid and liquid–lipid. The basic fundamentals of NLC
matrix are to create imperfections in highly ordered crystal matrix
of solid lipid thus increasing the payload of API and preventing
the expulsion of drug during storage154. Some of the remarkable
researches in LBDDS are exempliﬁed in Table 6.5.3. Solid dispersion
Solid dispersion (SD) technology is dispersion of one or more API in
an inert matrix at the molecular level, which was deﬁned in the early
1970s155. Active ingredients could exist in solubilized form, amor-
phous state or the crystalline state in an amorphous or crystalline-inert
matrix. Solid dispersion could dissolve drug immediately in contact in
the GI ﬂuid which lead to saturated or supersaturated solutions for
rapid absorption, and excess drug could precipitate in GI ﬂuid in very
ﬁnely divided state. Solid dispersions exist in various forms like
eutectic mixtures, crystalline solid solution, amorphous solid solution,
amorphous solid suspension, and controlled-release solid dispersion.
Eutectic mixtures consists of two compounds which are completely
miscible in the liquid state but to a very limited extent in the solidperoral absorption: Regulatory aspects and contemporary approaches to
2016), http://dx.doi.org/10.1016/j.apsb.2016.09.005
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Please cite this article as: Shekhawat Prachi, Pokharkar Varsha. Understanding
tackling solubility and permeability hurdles. Acta Pharmaceutica Sinica B (state. In a eutectic mixture, the melting point of the mixture is lower
than the melting point of the drug and carrier and is preferable because
both drug and carrier will crystallize simultaneously in the cooling
process, resulting in a dispersed state of drug in carrier, thus enhancing
the dissolution rate. Second is a solid solution which contains
microﬁne crystalline or amorphous API in crystalline solid dispersion.
Particle size of the API is reduced in such a system and the dissolution
rate is determined by the dissolution rate of the carrier. In such
systems API molecules are distributed substitutionally or interstitially
in which the API molecule can either substitute for the carrier
molecules in the crystal lattice or ﬁt into the interstices between the
solvent molecules in the crystal lattice84. In the case of an amorphous
solid dispersion API molecules are dispersed molecularly but irregu-
larly in the amorphous carrier and are classiﬁed into either an
amorphous solid solution or an amorphous solid suspension. In an
amorphous solid solution (glass solution) the drug and amorphous
carrier are completely miscible to form a molecularly homogenous
mixture while in the case of amorphous solid suspension small API
particles in an amorphous state are dispersed in the amorphous
carrier156. Various synthetic or natural origin cellulose polymers have
been utilized as carriers for solid dispersion. Surfactants and emulsi-
ﬁers can also be used as a carrier or additives in solid dispersion which
show signiﬁcant improvement in overcoming the problems with
amorphous solid dispersion in which a super saturation state of the
drug may cause precipitation of drug and decreases the concentration
in vitro and in vivo. Several methods have been used to prepare solid
dispersion such as the fusion method, solvent evaporation and melting
solvent method85. Numerous studies have demonstrated the marked
enhancement in oral bioavailability obtained by solid dispersion
technology as shown in Table 6.
5.4. Cyclodextrin complexation
Cyclodextrins (CD) are cyclic oligosaccharides derived from
starch containing six (α-CD), seven (β-CD), eight (γ-CD), nine
(δ-CD), ten (ε-CD) or more (α-1,4)-linked α-D-glucopyranose
units. Due to the chair conformation of the glucopyranose units,
the CD takes the shape of a truncated cone or torus rather than a
perfect cylinder. The primary hydroxyl groups are located on the
narrow side of the cone while secondary hydroxyl group are
located on the wider side. The central cavity of the CD molecule is
lined with skeletal carbons and ethereal oxygen of glucose which
provide it with a lipophilic character. Due to these chemical
properties, CDs are able to form inclusion complexes with many
drugs thereby increasing the drug solubility. No covalent bonds are
formed or broken during drug/CD complex formation. CD
derivatives of pharmaceutical interest include the hydroxypropyl
derivatives of β- and γ-CD, the randomly methylated β-CD,
sulfobutylether β-CD and the so-called branched CD such as
glucosyl-β-CD89. CD intervention is applicable mostly to BCS
class II and class IV drug compounds to alter their properties and
possibly shift them to a better class of BCS. Numerous studies
have reported the enhancement of oral bioavailability of poorly
water-soluble drugs by the CD inclusion complex (Table 6).
5.5. Micelles
Micelles are nano self-assemblies of amphipathic surfactant/poly-
mers with the hydrophobic part making the core and the hydro-
philic part forming the outer shell of assembly. These colloidal
structures have hydrodynamic diameter typically in range of 20–80peroral absorption: Regulatory aspects and contemporary approaches to
2016), http://dx.doi.org/10.1016/j.apsb.2016.09.005
Prachi Shekhawat, Varsha Pokharkar16nm. These structures solubilize poorly water-soluble drugs in a
hydrophobic core while the hydrophilic shell provides the protec-
tion against micelle–protein interaction which contributes to longer
blood circulation and stability. Prolonged circulation allows
maintaining the required therapeutic level of drug157. Along with
micellar solubilization of poorly soluble drugs, self-assembled
systems also have various advantages like cellular internalization,
subcellular localization and ligand-mediated targeting158.
5.6. Pharmaceutical co-crystals
Pharmaceutical co-crystals are simply a system in which at least
one of the molecular components is an API in conjunction with
another type of molecule called a co-former in the same crystal
lattice159. The Ofﬁce of Pharmaceutical Science Center for Drug
Evaluation and Research (CDER) at the FDA has also issued
guidance for Pharmaceutical co-crystals160. For ionisable com-
pounds' (anionic or cationic) salt formation is the cheapest and
simplest strategy to improve the solubility with extreme purity,
manufacturability (ﬂow property) and stability. With non-ionisable
compounds and with compounds having pKa in a range where salt
formation is not possible a pharmaceutical co-crystal is good
alternative. Traditionally, solid-state polymorphic forms of an API
are classiﬁed as either crystalline, amorphous, or solvate and
hydrate forms. Co-crystals are distinguishable from these tradi-
tional pharmaceutical solid-state forms. Unlike polymorphs, which
contain only the API within the crystal lattice, co-crystals are
composed of an API with a neutral guest compound (referred as a
conformer) in the crystal lattice. Similarly, unlike salts, where the
components in the crystal lattice are in an ionized state, a co-
crystal's components are in a neutral state and interact via nonionic
interactions. The non-API component in the co-crystal (co-former)
would be substances which are non-toxic with no adverse effects
and would appear on a Generally Recognized as Safe (GRAS) list.
Co-crystal solubility may or may not be greater than that of the
API and generally a co-former’s solubility tends to increase co-
crystal solubility161. Pharmaceutical cocrystallization has emerged
as a novel way to improve solubility and dissolution rate of poorly
soluble APIs as addressed by various researchers. Sanphui et al.162
prepared niclosamide co-crystal with theophylline which showed
good dissolution (5-fold) compared to the API. Mcnamara et al.163
prepared glutaric acid co-crystal for a poorly soluble API which
showed an improved dissolution rate by 18-fold when compared
with drug.
5.7. Prodrug
A prodrug is a masked form of a drug that is designed to be activated
once introduced into the body. A prodrug is viewed as a bioreversible
strategy of optimizing the delivery properties by maintaining the
original active structure. The rationale behind using this approach is to
optimize drug-like properties (manipulating with ADMET—absorp-
tion, distribution, metabolism, elimination and toxicity) as well as
prolonging the commercial life cycle of potential drug candidate. The
prodrug approach is widely used to increase solubility and dissolution
rate as well as improving the permeability of BCS class II and BCS
class IV drug. Prodrug strategy is an alternative to all above techniques
to improve solubility and dissolution rate by attaching the ionizable
group or polar neutral groups such as phosphates, amino acids or sugar
moieties164. However, increasing the hydrophilicity is always inter-
linked with poor permeation characteristics, and hence balance shouldPlease cite this article as: Shekhawat Prachi, Pokharkar Varsha. Understanding
tackling solubility and permeability hurdles. Acta Pharmaceutica Sinica B (be maintained between both. Practically insoluble drug cyclosporine A
was converted to a water-soluble prodrug to develop a water-based
concentrated eye drop for treatment of ocular disease165. Two water
insoluble drugs doxorubicin and dexmethasone were delivered in
combination using a macromolecule prodrug strategy having antitumor
activity. Dexmethasone was conjugated with a water-soluble poly-
saccharide which has amphiphilic character such that doxorubicin can
be encapsulated in the hydrophobic core of the micelle166. The classical
example is a phosphate prodrug of the HIV protease inhibitor
amprenavir. Amprenavir was formulated as a 150 mg capsule which
required 8 capsules to achieve a 1600-mg dose twice daily, which was
a clear disadvantage over other anti-AIDS drugs. The secondary
alcohol group of amprenavir was phosphorylated to produce fosam-
prenavir. Fosamprenavir is 10-fold more soluble than amprenavir and
formulated as a 700 mg tablet with reduced dosing to 2 tablets twice a
day making it a great commercial success167,168.
5.8. Mesoporous material
Increasing the effective surface area of a poorly soluble drug in
contact with the dissolution medium enhances the dissolution rate
which can be achieved by loading drug onto the mesoporous
material. Porous materials are classiﬁed as per IUPAC as micro-
porous (pore diameter o2 nm), macroporous (pore diameter
450 nm) and mesoporous material (pore diameter 2–50 nm).
Typical mesoporous material for drug delivery includes porous
silicon (Psi) mesoporous silica material such as SBA-15, MCM-48
and MSU, and some inorganic material like mesoporous Al2O3,
TiO2, carbon and hydroxycarbonate apatite
169-171. Mesoporous
material have an ordered unidirectional network (hexagonal, cubic
or lamellar structure) with extremely large surface area, pore
volume, narrow pore size distribution, strong absorption ability,
high drug loading capacity and chemical inertness thus improving
the dissolution kinetics for poorly soluble drugs99,172,173. Particle
size and surface area of ordered mesoporous materials (OMM)
inﬂuences drug loading and dissolution rate enhancement. It has
been reported that larger silica particles results in slower drug
release because of longer mesopore length174. PSi is produced by
chemical stain etching, metal assisted etching and electrochemical
etching method175. Mesoporous silicas are usually synthesized by
interaction between negatively charged silica tetraethylortho sili-
cate (TEOS) or sodium silicate and a positively charged surfactant
(quaternary ammonium salt) micelle that act as a structure-
directing agent which leads to formation of a ordered structure.
The surfactant is removed by calcinations or extraction, leaving a
porous silicate network176. Several model drugs from BCS class II
and BCS class IV have been tested using mesoporous material as a
carrier shown in Table 6.6. Conclusions
This review discusses the drug absorption process through oral
route. Better understanding of the physicochemical properties of a
drug and its relationship with physiology of body can predict API
bioavailability during the development phase. Further, we have
also tried to explain the fundamentals of BCS which is the
decision support system. It can be useful in selection of proper
formulation strategies and or proper excipient selection to deal
with solubility and permeability issues. For solubility/dissolution-
related hurdles techniques like particle size reduction, solid
dispersion, complexation, micellization, co-crystal formation canperoral absorption: Regulatory aspects and contemporary approaches to
2016), http://dx.doi.org/10.1016/j.apsb.2016.09.005
Understanding peroral absorption: regulatory aspects and contemporary approaches 17be feasible approaches. Poor permeability issues can be tackled
through lipid-based systems, various surface modiﬁcations, macro-
molecule architects like dendritic structures or polymeric conjunc-
tions. Thus, for BCS class II drugs techniques solving solubility/
dissolution issue can be beneﬁcial while, for BCS IV compounds
combining both the strategies, viz., solubility and permeability
solving techniques can be more preferable.Acknowledgment
We thank Department of Science and Technology, New Delhi for
providing ﬁnancial assistance under Women Scientist Scheme-A
(SR/WOS-A/LS-248/2012).References
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